Compare Novartis AG (NVS) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Utilities Select Sector SPDR Fund — how do they compare? Novartis AG trades at $142.98 (market cap $268.57B), while Utilities Select Sector SPDR Fund trades at $41.26 (market cap $23.60B). The key difference: Novartis AG is far larger — about 11.4× Utilities Select Sector SPDR Fund's market cap, and Novartis AG pays a 3.31% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| NVS | XLU | |
|---|---|---|
Market Cap | $268.57B | $23.60B |
Volume | 1,532,573 | 28,758,237 |
Sector | Health | — |
52-Week High | $168.62 | $47.73 |
52-Week Low | $121.80 | $39.25 |
Typical Hold Time | 82 Days | 80 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
XLU trades at $41.15, down slightly by 0.02% with mixed technical signals showing a bullish moving average trend but neutral oscillators. The ETF recently hit 52-week lows amid sector-wide pressure from rising interest rates. Recent news highlights utility stocks as oversold with potential defensive appeal during market volatility.
The outlook remains cautious due to interest rate sensitivity, though oversold conditions may present opportunity for defensive positioning. Key risks include continued rate hikes and regulatory pressures, while potential upside exists if utilities regain favor as AI power demand grows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
